CFM possesses patented technology that provides a new, much-improved treatment of various acute traumatic indications such as a myocardial infarction, second-and third-degree burns, general & diabetic wounds, and other general traumatic injuries like acute kidney injury (AKI), multiple organ dysfunction syndrome (MODS) and stroke.

The company has headquarters in the Netherlands and at the Astra Zeneca BioVentureHub in Sweden.